June 24, 2010
Pharmacosmos sponsors the ERA-EDTA 2010 Congress and brings
together leading international experts in nephrology to discuss
improving treatment of anaemia in Chronic Kidney Disease (CKD) with
IV iron therapy in a Satellite Symposium.
Healthcare professionals attending the ERA-EDTA Congress will
have the opportunity to learn about the latest outcomes from the
TREAT study in relation to improving the treatment of anaemia in
patients with CKD using IV iron therapy. Pharmacosmos, a leading
developer of medicines for the treatment of iron deficiency, has
gathered a panel of international experts in nephrology to talk
about the future role of IV iron therapy at the Satellite
Symposium, "The Future is Now" Sunday, June 27th at
12:45 pm, Room 14A, ICM first floor.
This symposium will focus on the management of iron deficiency
anaemia and the new opportunity with Monofer® (iron isomaltoside
1000) among patients with CKD. The presentations will be followed
by a panel discussion.
According to symposium Chair, Dr. Rajiv Agarwal, who is a
leading international expert in clinical and translational research
in nephrology and Professor of Medicine at Indiana University
School of Medicine, Indianapolis, IN, USA, "We now have three
outcome trials that demonstrate harms associated with complete
correction of haemoglobin. These trials demonstrate a paradox. The
paradox is that when higher haemoglobin is achieved, better
outcomes are seen. However, when higher haemoglobin is targeted,
worse long-term outcomes are observed. In part, this paradox may be
attributed to hyporesponse to erythropoietin stimulating agents.
Among various reasons for this hyporesponse is iron deficiency. A
condition that is underappreciated but treatable. Previous symposia
have speculated about the future role of IV iron. The title of this
symposium was chosen to communicate that the future has arrived -
the future is now."
Iron deficiency anaemia is a significant problem in patients
with CKD. Monofer® (iron isomaltoside 1000), developed by
Pharmacosmos and recently launched in the EU, is the only IV iron
solution that offers both the widest accepted dose range and no
test dose requirement1. It is indicated for the
treatment of patients with iron deficiency anaemia*, and can be
administered to patients with various underlying conditions.
For more information about the Satellite Symposium, visit Pharmacosmos.com/ERA-EDTA.
For more information about Monofer®, visit
Lars Christensen, M.D.
President and CEO
T: +45 5948 5959
1) Core SPC
* When oral iron preparations are ineffective
or cannot be used. Where there is a clinical need to deliver iron
rapidly. The diagnosis of iron deficiency anaemia should be based
on appropriate laboratory tests (e.g. serum ferritin, serum iron,
transferrin saturation or hypochromic red cells).
© 2010 Pharmacosmos A/S. Monofer® is a
registered trademark of Pharmacosmos A/S.
About Pharmacosmos A/S
Pharmacosmos develops and markets
medicines for the treatment of iron deficiency. A research-based
company, its ongoing R&D programme focuses on improving the
treatment options for healthcare professionals, patients suffering
from iron deficiency and veterinary treatments. .
Pharmacosmos is a family-owned
Danish company and operates in more than 50 countries across
Europe, the Americas and Asia. Its facilities are approved by both
the Danish Medicines Agency and the US Food & Drug